Immunopharmacological in vitro effects of Eleutherococcus senticosus extracts.
The objective of these investigations was to further elucidate the immunopharmacological profile of fluid extracts of Eleutherococcus senticosus and to identify the specific role of its characteristic eleutherosides B and E. An ethanolic dry extract of Eleutherococcus senticosus was used as starting material for the isolation of the eleutherosides B and E. Immunopharmacological studies included expression of major histocompatibility complex class I and II molecules by rat bone marrow-derived mononuclear phagocytes, human lymphocyte marker flow cytometry, and in vitro testing of human lymphocyte functions. In contrast to the isolated eleutherosides B and eleutherosides E and the re-mixed eleutherosides B and E, the whole ethanolic fluid extract of Eleutherococcus senticosus was able to induce and enhance interleukin-1 and interleukin-6 but not interleukin-2 production in vitro. The effective concentration of the whole ethanolic extract ranged from 1.0-0.1 mg/ml for the enhancement of interleuking-1 alpha production and 1.0-0.03 mg/ml for the enhancement of interleukin-6 production. It is concluded that the observed enhancing immunopharmacological activities on acute phase response mediators are best exhibited by the induction with whole ethanolic extracts whereas the species-specific and characteristic eleutherosides B and E are not associated with these activities.
Steinmann
G G
GG
Boehringer Ingelheim, Biberach/Riss, Germany. gerhard.steinmann@bc.boehringer-ingelheim.com
Esperester
A
A
Joller
P
P
D000276:Adjuvants, Immunologic / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D017252:CD3 Complex / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects; D016207:Cytokines / Q000096:biosynthesis; D005805:Genes, MHC Class I; D005802:Genes, MHC Class II; D005960:Glucosides / Q000302:isolation & purification / Q000494:pharmacology*; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D017705:Lignans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009000:Monocytes / Q000187:drug effects; D019798:Neopterin / Q000096:biosynthesis; D010666:Phenylpropionates; D010946:Plants, Medicinal / Q000737:chemistry*; D051381:Rats; D013055:Spectrophotometry, Infrared; D013056:Spectrophotometry, Ultraviolet; D001613:beta 2-Microglobulin / Q000096:biosynthesis
D000276:Adjuvants, Immunologic; D017252:CD3 Complex; D016207:Cytokines; D005960:Glucosides; D006684:HLA-DR Antigens; D017705:Lignans; D010666:Phenylpropionates; D001613:beta 2-Microglobulin; D019798:Neopterin; C421885:eleutheroside E; C028305:syringin